C3G is estimated to affect around one person per million in the US, a small patient population, but is one of a series of ...

Apple, Microsoft, Alphabet, Amazon, and Meta Platforms will remain in focus as these firms will release their third quarter ...

Massachusetts stands at the forefront of biotechnology innovation, particularly in sustainable solutions. With a rich history ...

Choosing a random dividend stock out of a hat won't do, though. Some are much more attractive than others. Which ones should ...

The advocacy groups said at the time that the deal could constrain competitors such as Amgen, Pfizer, Roche and AstraZeneca, ...

As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of ...

Monopar Therapeutics is handing over cash and equity to AstraZeneca to further develop a treatment for Wilson disease that ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. Its ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.